

CLAIM AMENDMENTS:

This listing of claims will replace all prior versions, and listings, of claims in the application.

LISTING OF CLAIMS:

1. (previously amended) A method for the treatment of Hodgkin's Disease in a subject comprising administering to the subject, in an amount effective for said treatment, (a) an antibody that (i) immunospecifically binds CD30 and (ii) exerts a cytostatic or cytotoxic effect on a Hodgkin's Disease cell line, wherein said antibody exerts the cytostatic or cytotoxic effect on the Hodgkin's Disease cell line in the absence of conjugation to a cytostatic or cytotoxic agent and in the absence of cells other than cells of said Hodgkin's Disease cell line; and (b) a pharmaceutically acceptable carrier,
2. (original) The method of claim 1, wherein the antibody is human, humanized or chimeric.
3. (original) The method of claim 1, further comprising administering chemotherapy to said subject.
4. (original) The method of claim 1, wherein the antibody is conjugated to a cytotoxic agent.
5. (original) The method of claim 1, wherein the antibody is a fusion protein comprising the amino acid sequence of a second protein that is not an antibody.
6. (original) The method of claim 4 or 5, further comprising administering chemotherapy to said subject.
7. (previously amended) The method of claim 1, wherein the cytostatic or cytotoxic effect is exhibited upon performing a method comprising:
 - (a) contacting a culture of the Hodgkin's Disease cell line with the antibody, said culture being of about 5,000 cells in a culture area of about 0.33 cm², said contacting being for a period of 72 hours;
 - (b) exposing the culture to 0.5 μ Ci of ³H-thymidine during the final 8 hours of said 72-hour period; and
 - (c) measuring the incorporation of ³H-thymidine into cells of the culture, wherein the antibody has a cytostatic or cytotoxic effect on the Hodgkin's Disease cell line if the cells of the culture have reduced ³H-thymidine incorporation compared to cells of

the same Hodgkin's Disease cell line cultured under the same conditions but not contacted with the antibody.

8. (previously amended) A method for the treatment of Hodgkin's Disease in a subject comprising administering to the subject an amount of a protein, which protein (a) competes for binding to CD30 with monoclonal antibody AC10 or HeFi-1, and (b) exerts a cytostatic or cytotoxic effect on a Hodgkin's Disease cell line, which amount is effective for the treatment of Hodgkin's Disease.

9-10. (canceled)

11. (currently amended) A method for the treatment of Hodgkin's Disease in a subject comprising administering to the subject an amount of a protein, which protein (a) comprises an amino acid sequence that has at least 95% identity to SEQ ID NO:2 or SEQ ID NO:10, and (b) immunospecifically binds CD30, which amount is effective for the treatment of Hodgkin's Disease.

12. (canceled)

13. (previously amended) The method of any one of claims 8 or 11, wherein the protein is a human, humanized or chimeric antibody.

14. (previously amended) The method of any one of claims 8 or 11, further comprising administering chemotherapy to said subject.

15. (previously amended) The method of any one of claims 8 or 11, wherein the protein is conjugated to a cytotoxic agent.

16. (previously amended) The method of any one of claims 8 or 11, wherein the protein is a fusion protein comprising the amino acid sequence of a second protein.

17. (original) The method of claim 15, further comprising administering chemotherapy to the subject.

18. (original) The method of claim 16, further comprising administering chemotherapy to the subject.

19. (previously amended) The method of any one of claims 8 or 11, wherein the cytostatic or cytotoxic effect is exhibited upon performing a method comprising:

(a) contacting a culture of the Hodgkin's Disease cell line with the protein, said culture being of about 5,000 cells in a culture area of about 0.33 cm², said contacting being for a period of 72 hours;

(b) exposing the culture to 0.5 μ Ci of 3 H-thymidine during the final 8 hours of said 72-hour period; and

(c) measuring the incorporation of 3 H-thymidine into cells of the culture, wherein the protein has a cytostatic or cytotoxic effect on the Hodgkin's Disease cell line if the cells of the culture have reduced 3 H-thymidine incorporation compared to cells of the same Hodgkin's Disease cell line cultured under the same conditions but not contacted with the protein.

20-66. (canceled)

67. (new) A method for the treatment of Hodgkin's Disease in a subject comprising administering to the subject, in an amount effective for said treatment, (a) an antibody that (i) immunospecifically binds CD30 and (ii) exerts a cytostatic or cytotoxic effect on a Hodgkin's Disease cell line, wherein the antibody exerts the cytostatic or cytotoxic effect on the Hodgkin's Disease cell line in the absence of conjugation to a cytostatic or cytotoxic agent and (b) a pharmaceutically acceptable carrier, wherein the cytostatic or cytotoxic effect is exhibited upon performing a method comprising:

(A) immobilizing said antibody in a well, said well having a culture area of about 0.33 cm²;

(B) adding 5,000 cells of the Hodgkin's Disease cell line in the presence of only RPMI with 10% fetal bovine serum or 20% fetal bovine serum to the well;

(C) culturing the cells in presence of only said antibody and RPMI with 10% fetal bovine serum or 20% fetal bovine serum for a period of 72 hours to form a Hodgkin's Disease cell culture;

(D) exposing the Hodgkin's Disease cell culture to 0.5 μ Ci/well of 3 H-thymidine during the final 8 hours of said 72-hour period; and

(E) measuring the incorporation of 3 H-thymidine into cells of the Hodgkin's Disease cell culture,

wherein the antibody has a cytostatic or cytotoxic effect on the Hodgkin's Disease cell line if the cells of the Hodgkin's Disease cell culture have reduced 3 H-thymidine incorporation compared to cells of the same Hodgkin's Disease cell line cultured under the same conditions but not contacted with the antibody.